breast adenocarcinoma (Cancer)
Information
- Disease name
- breast adenocarcinoma
- Disease ID
- DOID:3458
- Description
- "A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast." [url:http\://www.virtualmedicalcentre.com/diseases.asp?did=696]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02488967 | Active, not recruiting | Phase 3 | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | July 26, 2015 | October 31, 2026 |
| NCT02515110 | Active, not recruiting | N/A | Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer | August 4, 2015 | January 24, 2025 |
| NCT02530489 | Active, not recruiting | Phase 2 | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | February 4, 2016 | December 31, 2025 |
| NCT00310180 | Active, not recruiting | Phase 3 | Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | April 7, 2006 | September 30, 2030 |
| NCT01245712 | Active, not recruiting | Phase 2 | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | November 15, 2010 | December 31, 2032 |
| NCT06234488 | Active, not recruiting | Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study | December 8, 2023 | December 30, 2025 | |
| NCT01730833 | Active, not recruiting | Phase 2 | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | July 17, 2013 | December 31, 2024 |
| NCT04769960 | Active, not recruiting | Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy | February 19, 2021 | February 19, 2025 | |
| NCT02957968 | Active, not recruiting | Phase 2 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | January 24, 2017 | February 28, 2025 |
| NCT02115282 | Active, not recruiting | Phase 3 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | March 29, 2014 | June 14, 2024 |
| NCT00433511 | Active, not recruiting | Phase 3 | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | November 2, 2007 | February 22, 2025 |
| NCT02453620 | Active, not recruiting | Phase 1 | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | February 12, 2016 | August 30, 2024 |
| NCT00005970 | Completed | Phase 3 | Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer | May 19, 2000 | January 27, 2010 |
| NCT00869206 | Completed | Phase 3 | Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | March 2009 | January 2017 |
| NCT02282345 | Completed | Phase 2 | Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer | April 16, 2015 | June 7, 2022 |
| NCT03094052 | Completed | Phase 2 | Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | October 9, 2018 | October 31, 2022 |
| NCT03106415 | Completed | Phase 1/Phase 2 | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | September 27, 2017 | May 19, 2022 |
| NCT03250676 | Completed | Phase 1/Phase 2 | Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | August 17, 2017 | October 26, 2023 |
| NCT04535323 | Completed | Phase 1 | Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer | September 23, 2020 | January 10, 2024 |
| NCT04857697 | Completed | Early Phase 1 | Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer | July 1, 2021 | March 8, 2023 |
| NCT06401889 | Not yet recruiting | Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy | June 1, 2024 | June 2027 | |
| NCT05579366 | Recruiting | Phase 1/Phase 2 | PRO1184 for Advanced Solid Tumors | December 7, 2022 | April 2026 |
| NCT04517838 | Recruiting | Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer | July 27, 2020 | July 27, 2028 | |
| NCT05183828 | Recruiting | Phase 4 | Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | January 23, 2022 | December 31, 2024 |
| NCT04197687 | Recruiting | Phase 2 | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | February 20, 2020 | January 15, 2025 |
| NCT05447910 | Recruiting | Phase 2 | Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer | July 21, 2022 | June 15, 2025 |
| NCT03432741 | Suspended | Phase 1 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | March 27, 2018 | May 1, 2026 |
| NCT02037529 | Suspended | Phase 3 | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer | January 17, 2014 | December 31, 2023 |
| NCT03137693 | Terminated | N/A | Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer | November 29, 2017 | January 27, 2020 |
| NCT04139993 | Terminated | Phase 1 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | August 31, 2020 | January 11, 2023 |
| NCT01697293 | Terminated | Phase 1/Phase 2 | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer | January 2012 | June 2020 |
| NCT02824575 | Terminated | Phase 1 | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | July 2016 | December 27, 2021 |
| NCT01942629 | Unknown status | Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas | October 2013 | December 2015 | |
| NCT04300829 | Unknown status | Phase 3 | Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients | June 6, 2020 | October 9, 2022 |
| NCT03666819 | Withdrawn | Phase 2 | Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy | September 10, 2018 | September 10, 2021 |
- Disase is a (Disease Ontology)
- DOID:3459
- Cross Reference ID (Disease Ontology)
- NCI:C5214
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:865954003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0858252
- Exact Synonym (Disease Ontology)
- Mammary adenocarcinoma
- Disase Synonym (Disease Ontology)
- adenocarcinoma of breast